Orelabrutinib not checked
Beijing InnoCare Pharma Tech Co., Ltd. · ICP-022 · ICP-022+ R-CHOP
FollowEvery change as it happens, and a Monday email
Trials
8 active
26 in total · 3 in the EU
What this is
- How it works
- Blocks BTK, an enzyme B cells (a type of immune cell) need to grow and work. Used against some blood cancers and immune diseases.-brutinib: Bruton's tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Participants receive orelabrutinib 150 mg oral once daily continuous dosing; each cycle is 28 days.”In the company’s words, NCT07896590 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Marginal Zone Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (MZL), Multiple Sclerosis (MS) Primary Progressive, Secondary Progressive Multiple Sclerosis, Mantle Cell Lymphoma, Relapsed or Refractory Mantle Cell Lymphoma (MCL), Hematologic Malignancies, Part 1:r/r B-cell Malignancies and 1 more
- Main trialPhase 3
- “Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma”In the company’s words, NCT06082102 on ClinicalTrials.gov
- Other names
- ICP-022 · ICP-022+ R-CHOP
Other drugs for Relapsed/Refractory Marginal Zone Lymphoma
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- MesutoclaxBeijing InnoCare Pharma Tech Co., Ltd. · Phase 3
- OdronextamabRegeneron · Phase 3
- TafasitamabIncyte Corporation · MorphoSys AG · Phase 3
- TacabrutidegBeOne Medicines (BeiGene) · Phase 1/2
- NemtabrutinibMerck & Co. · Phase 1/2
Coming up7
- 31 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
- Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2030Phase 3 trial completes · ClinicalTrials.gov
- Jun 2030Phase 3 trial completes · ClinicalTrials.gov
- 25 Nov 2030Phase 2/3 trial completes · ClinicalTrials.gov
- 25 Jun 2031Phase 3 trial completes · ClinicalTrials.gov
- Oct 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Aug 2028 | Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma | |
| Phase 3Not yet recruiting | Oct 2028 | Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma | |
| Phase 3Recruiting | Jun 2030 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | |
| Phase 3Recruiting | Jun 2030 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | |
| Phase 3Recruiting | 25 Jun 2031 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | |
| Phase 3Not yet recruiting | Oct 2032 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). | |
| Phase 2/3Recruiting | 25 Nov 2030 | ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) | |
| Phase 1/2Active, not recruiting | 30 Jun 2026 | A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies | |
| Phase 3Unknown | 30 Jul 2024 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | |
| Phase 3Unknown | 30 Dec 2024 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | |
| Phase 3Unknown | 31 Dec 2025 | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia | |
| Phase 2Completed | 5 Nov 2021 | A Study of ICP-022 in Patients With R/R DLBCL | |
| Phase 2Completed | 27 Dec 2023 | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | |
| Phase 2Unknown | 30 Dec 2023 | A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia | |
| Phase 2Unknown | 31 Dec 2023 | A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | |
| Phase 2Completed | 9 Jan 2024 | A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia | |
| Phase 2Completed | 10 Dec 2024 | Evaluating Different Doses of Orelabrutinib in MCL | |
| Phase 2Unknown | 25 Aug 2025 | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus | |
| Phase 2Unknown | 25 Feb 2026 | A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis | |
| Phase 1/2Completed | 10 Apr 2020 | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | |
| Phase 1/2Completed | 28 Apr 2022 | A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE) | |
| Phase 1/2Unknown | 31 Dec 2022 | A Study to Evaluate ICP-022 in Patients With CLL/ SLL | |
| Phase 1/2Unknown | 30 Dec 2025 | A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma | |
| Phase 1Completed | 4 Jan 2022 | DDI Study of Orelabrutinib | |
| Phase 1Unknown | 30 Jun 2023 | Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects | |
| Phase 1Unknown | 30 Dec 2023 | Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026